Bargain Hunters Alert - BNGO Zacks Equity Res
Post# of 99
(Total Views: 87)
Posted On: 09/09/2025 6:56:53 AM
Bargain Hunters Alert - BNGO
Zacks Equity Research: “Fast-Paced Momentum at a Bargain”
Zacks published a report on September 8, 2025, spotlighting BNGO as one of its top momentum-at-a-bargain picks. The analysis notes a 37.1% four-week price gain and a 12-week gain of 9.3%, earning Bionano an “A” Momentum Style Score alongside a Zacks Rank #2 (Buy). The story argues that strong earnings-estimate revisions underpin the stock’s run.
Investing.com released a full transcript of Erik Holmlin’s H.C. Wainwright presentation, dubbing it “Strategic Shift to Digital Pathology.”
FierceBiotech and GenomeWeb have both sampled excerpts from Bionano’s recent publications and CPT-code milestones, highlighting OGM’s growing role in hematologic-malignancy diagnostics.
BioCentury is tracking Bionano’s reimbursement progress under new molecular-pathology CPT codes, signaling wider clinical uptake.
Across equity-research screens, industry transcripts, and a robust press-release cadence, Bionano Genomics is undeniably in the spotlight.
Zacks Equity Research: “Fast-Paced Momentum at a Bargain”
Zacks published a report on September 8, 2025, spotlighting BNGO as one of its top momentum-at-a-bargain picks. The analysis notes a 37.1% four-week price gain and a 12-week gain of 9.3%, earning Bionano an “A” Momentum Style Score alongside a Zacks Rank #2 (Buy). The story argues that strong earnings-estimate revisions underpin the stock’s run.
Investing.com released a full transcript of Erik Holmlin’s H.C. Wainwright presentation, dubbing it “Strategic Shift to Digital Pathology.”
FierceBiotech and GenomeWeb have both sampled excerpts from Bionano’s recent publications and CPT-code milestones, highlighting OGM’s growing role in hematologic-malignancy diagnostics.
BioCentury is tracking Bionano’s reimbursement progress under new molecular-pathology CPT codes, signaling wider clinical uptake.
Across equity-research screens, industry transcripts, and a robust press-release cadence, Bionano Genomics is undeniably in the spotlight.
(0)
(0)